|
| dbGaP Submitter Subject ID (ID2) | Coriell Sample ID | Consent | Control | Gender | Race | Age | Baseline Max AMD Severity | Final Max AMD Severity |
| AR2_0928 | ED148959 | General Research Use | No | Female | White | 64 | 5 - AREDS AMD Severity Scale Step 4 | 5 - AREDS AMD Severity Scale Step 5 |
| AR2_2338 | ED148031 | General Research Use | No | Male | White | 58 | 5 - AREDS AMD Severity Scale Step 4 | 4 - AREDS AMD Severity Scale Step 4 |
| AR2_3153 | ED149035 | General Research Use | No | Female | White | 77 | 5 - AREDS AMD Severity Scale Step 5 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_3582 | ED148753 | General Research Use | No | Male | White | 69 | 5 - AREDS AMD Severity Scale Step 5 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_4159 | ED149652 | General Research Use | No | Male | White | 81 | 5 - AREDS AMD Severity Scale Step 4 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_0829 | ED150010 | General Research Use | No | Male | White | 75 | 5 - AREDS AMD Severity Scale Step 5 | 8 - AREDS AMD Severity Scale Step 8 |
| AR2_1357 | ED150008 | General Research Use | No | Female | White | 51 | 5 - AREDS AMD Severity Scale Step 5 | 5 - AREDS AMD Severity Scale Step 5 |
| AR2_0851 | ED149241 | General Research Use | No | Male | White | 76 | 5 - AREDS AMD Severity Scale Step 4 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_1184 | ED149830 | General Research Use | No | Female | White | 81 | 5 - AREDS AMD Severity Scale Step 5 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_1719 | ED149715 | General Research Use | No | Female | White | 79 | 5 - AREDS AMD Severity Scale Step 5 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_2582 | ED149091 | General Research Use | No | Male | White | 67 | 5 - AREDS AMD Severity Scale Step 3 | 4 - AREDS AMD Severity Scale Step 4 |
| AR2_2602 | ED149960 | General Research Use | No | Female | White | 75 | 5 - AREDS AMD Severity Scale Step 5 | 10 - Central GA |
| AR2_3286 | ED148364 | General Research Use | No | Male | White | 83 | 5 - AREDS AMD Severity Scale Step | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_4097 | ED148083 | General Research Use | No | Male | White | 70 | 5 - AREDS AMD Severity Scale Step 4 | 5 - AREDS AMD Severity Scale Step 5 |
| AR2_0727 | ED149743 | General Research Use | No | Male | White | 71 | 5 - AREDS AMD Severity Scale Step 4 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_1059 | ED149372 | General Research Use | No | Female | Black or African American | 66 | 5 - AREDS AMD Severity Scale Step 5 | 5 - AREDS AMD Severity Scale Step 5 |
| AR2_1150 | ED149263 | General Research Use | No | Female | White | 55 | 5 - AREDS AMD Severity Scale Step 5 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_1449 | ED148851 | General Research Use | No | Male | White | 75 | 5 - AREDS AMD Severity Scale Step 5 | 5 - AREDS AMD Severity Scale Step 5 |
| AR2_1798 | ED149966 | General Research Use | No | Female | White | 74 | 5 - AREDS AMD Severity Scale Step 5 | 8 - AREDS AMD Severity Scale Step 8 |
| AR2_2348 | ED149162 | General Research Use | No | Male | White | 75 | 5 - AREDS AMD Severity Scale Step 5 | 5 - AREDS AMD Severity Scale Step 5 |